他汀类药物可降低炎症性肠病患者发生结直肠癌风险:meta分析

Association between statin use and colorectal cancer risk in IBD patients:a meta-analysis

目的探讨他汀类药物在降低炎症性肠病(inflammatory bowel disease,IBD)患者发生结直肠癌风险中是否有作用。方法系统检索了Pubmed、Embase、Cochrane Library、Web of Science、中国知网、维普数据库、万方数据库,筛选出2020年6月1日之前发表的符合纳入标准的文献,纳入阿托伐他汀治疗IBD的试验。使用RevMan 5.3软件对发生结直肠癌发生率进行meta分析,并用I^2检验分析其异质性。结果研究最终纳入了4篇文献;共涉及13469例IBD患者,其中接受他汀类药物治疗的有1661例,没有接受他汀类药物治疗的有11808例。meta分析结果显示他汀类药物可降低IBD患者发生结直肠癌的风险,差别有统计学意义(OR=0.66,95%CI:0.46~0.93,P=0.02);且异质性检验提示纳入文献之间异质性低(I^2=35%,P=0.21),漏斗图提示文献之间无发表偏移存在。结论他汀类药物可降低IBD患者罹患结直肠癌的风险。

Objective To clarify the role of statin in reducing the risk of colorectal cancer in IBD.Methods A comprehensive literature search in Pubmed,Embase,Cochrane Library,Web of Science,CnKI,Viper database and Wanfang database was undertaken through June 1,2020 looking for eligible studies.Pooled Odds Ratio(OR)estimates and 95%confidence intervals(CIs)were used to calculate estimated effect.The meta performed with RevMan 5.3 software,and the heterogeneity was analyzed with I^2 test.Results Four articles involving in 13469 patients with IBD were included in the study.Among 13469 patients,1661 cases were treated with statins and 11808 were treated without statins.The result showed that statins reduced the risk of colorectal cancer in patients with IBD,and the difference was statistically significant(OR=0.66,95%CI:0.46-0.93,P=0.02).Moreover,the heterogeneity test indicated that the heterogeneity among the included literatures was low(I^2=35%,P=0.21).Funnel plot indicated that there was no publication bias between the literatures.Conclusions Statin reduced the incidence risk of colorectal cancer in IBD patients.